doi: 10.3389/fimmu.2025.1631074 Received 19 May 2025 Accepted 30 September 2025 Published 15 October 2025 Volume 16 - 2025 Edited by Liliana Gabriela Popa, Carol Davila University of Medicine and Pharmacy, Romania Reviewed by Mauro Alaibac, University of Padua, Italy Tetsuro Kobayashi, Riken Yokohama, Japan Updates Copyright 2025 Wang, Cao, Liu, Xiong, Xu and Bian
Konopleva MY, Walter RB, Faderl S, Jabbour E, Zeng Z, Borthakur G , Ruvolo P, Huang X, Kadia T, Feliu J, Burger JA, Andreeff M, Liu W, Kornblau SM, Baggerly K, Estey E, Hagop Kantarjian H
Tirzepatide (GLP-1/GIP Dual Agonist) Pathway: Tirzepatide targets GLP-1 + GIP
Effect of the intake of a snack containing dietary fiber on postprandial glucose levels
Efforts have been directed towards optimizing kidney-to-liver ratios and enhancing drug distribution to the kidney through receptor and transporter-directed strategies are effective